

04/27/00
JC625 U.S. PTO

4-28-00

A

Attorney Docket No.: 5694.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

JC625 U.S. PTO
09/559764
04/27/00

Re: U.S. Patent Application for
Title: Inhibition Of Bradykinn Release
Applicants: Flodgaard et al.

Sir:

Express Mail Label No. EL473439981US

Date of Deposit : April 27, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Unexecuted Combined Declaration and Power of Attorney
4. Sequence Listing
5. Diskette containing Sequence Listing
6. Verified Statement

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Miriam Kelly
(Name of person mailing paper(s) or fee)

Miriam Kelly
(Signature of person mailing paper(s) or fee)

Mailing Address:
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123

09559764, 042700

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231



Express Mail Label No. EL473439981US
Date of Deposit April 27, 2000

Sir:

This is a request for filing a patent application under 37 C.F.R. 1.53(b) of
Applicant(s): Flodgaard et al.

Title: Inhibition Of Bradykinn Release

60 pages of specification 13 sheets of drawings

3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:	\$ 690.00
Total Claims: $42 - 20 = 22 \times 18 =$	\$ 396.00
Independent Claims: $12 - 3 = 9 \times 78 =$	\$ 702.00
Total Fee:	\$1,788.00


Priority of U.S. provisional application nos. 60/132,748 and 60/157,384 filed on
April 29, 1999 and October 1, 1999 is claimed under 35 U.S.C. 119.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of
North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$1,788, to Novo Nordisk of North
America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: April 27, 2000


Cheryl H. Agris, Reg. No. 34,086
Outside Counsel for Novo Nordisk
of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

002240 4926550

Attorney Docket No. 5694.200-US
Patent Application entitled: "Inhibition Of Bradykinn Release"
Applicants: Flodgaard et al.

The USPTO hereby acknowledges receipt of the following:

1. Express Mail Certificate
2. Application Fee Transmittal (in duplicate)
3. Patent Application
4. Unexecuted Combined Declaration and Power of Attorney
5. Sequence Listing
6. Diskette containing Sequence Listing
7. Verified Statement

CLHA/MKcl
April 27, 2000
VIA US Express Mail, label no.

EL473439981US

HCW

Attorney Docket No. 5694.200-US
Patent Application entitled: "Inhibition Of Bradykinn Release"
Applicants: Flodgaard et al.

The USPTO hereby acknowledges receipt of the following:

1. Express Mail Certificate
2. Application Fee Transmittal (in duplicate)
3. Patent Application
4. Unexecuted Combined Declaration and Power of Attorney
5. Sequence Listing
6. Diskette containing Sequence Listing
7. Verified Statement

CLHA/MKcl
April 27, 2000
VIA US Express Mail, label no.

EL473439981US

JC625 U.S. PTO
09/559764

